Action of anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors

Current Pharmaceutical Design

Volumn 10, Issue 32, 2004, Pages 4039-4053

  Imamichi, Tomozumi ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Drug resistance; HIV 1; Mutations; PR; PR inhibitors; RT; RT inhibitors

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CAPRAVIRINE; CARBOVIR; DACTINOMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROSS RESISTANCE; DIABETES MELLITUS; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFE CYCLE; LIPODYSTROPHY; LONG TERM CARE; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 10644280992     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382440     Document Type: Review

References (208)

1. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin Protection of T Cells in vitro against Infectivity and Cytopathic Effect of HTLV-III. Science 1984; 226: 172-4.
2. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, et al. 3′-Azido-3′-deoxythymidine (BW A509U : an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Nat Acad Sci USA 1985; 82: 7096-100.
3. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-1-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985; 229: 563-6.
4. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249:1533-44.
5. Gulick RM, Mellors JW, Havlir D, Eton JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
7. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 338: 853-60.
8. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280: 1871-3.
9. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
10. Vogt PK. In: Coffin JM, Hughes SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor Laboratory Press. 1977; 1-25.
11. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872.
12. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
13. Donis RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000; 151: 179-14.
14. Bentz J. Membrane fusion mediated by coiled coils: a hypothesis. Biophys J 2000; 78: 886-900.
15. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151: 413-23.
16. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-30.
17. Baldwin CE, Sanders RW, Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003; 10: 1633-42.
18. LaBranche CC, Galasso G, Moore JM, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Research 2001; 50: 95-115.
19. Telesnitsky A, Goff SP. In: Coffin JM, Hughes SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor Laboratory Press, 1977; 121-160.
20. Pommier Y, Marchand C, Neamati N, Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res 2000; 47: 139-48.
21. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001 - 2002 update. Curr Pharm Des 2003; 9: 1789-802.
22. Neamati N, Marchand C, Pommier Y. HIV-1 integrase inhibitors: past, present, and future. Adv Pharmacol 2000; 49: 147-65.
23. Vogt VM. In: Coffin JM, Hughes. SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor Laboratory Press. 1977; 27-69.
24. Robinson AB, Graves BJ. In: Coffin JM, Hughes SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor Laboratory Press. 1977; 205-261.
25. Turpin JA, Buckheit RW Jr, Derse D, Hollingshead M, Williamson K, Palamone C, et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother 1998; 42: 487-94.
26. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, et al. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998; 53: 1097-103.
27. Swanstrom R, Wills JW. In: Coffin JM, Hughes SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor Laboratory Press. 1977; 263-334.
28. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000; 74: 8252-61.
29. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-8.
30. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302: 1056-60.
31. Goff SP. Death by deamination: a novel host restriction system for HIV-1. Cell 2003; 114: 281-3.
32. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8:153-64.
33. Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329: 351-4.
34. Kramer RA, Schaber MD, Skalka AM, Ganguly K, Wong-Staal F. Reddy EP. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986; 231: 15804.
35. Graves MC, Lim JJ, Heimer EP, Kramer RA. An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci USA 1988; 85: 2449-53.
36. Le Grice SF, Mills J, Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988; 7: 2547-53.
37. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90.
38. Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW. Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 2003; 34: 398-402.
39. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science 1992; 256: 1783-90.
40. Arnold E, Jacobo-Molina A, Nanni RG, Williams RE, Lu X, Ding J, et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature 1992; 357: 85-9.
41. Jacobo-Molina A, Ding J, Nanni RG, Lark AD, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Porc Natl Acad Sci USA 1993, 90: 6320-4.
42. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′, 3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986; 83: 1911-5.
43. Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 1987; 325: 773-8.
44. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′ -azido-3-deoxythymidine and Selective Interaction of the 5′ -triphosphate with Human Immunodeficiency Virus Reverse Transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-7.
45. Sherley JL, Thomas JK. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263: 8350-8.
46. Imamichi T, Murphy MA, Adelsbergers JW, Yang J, Watkins CM, Berg SC, et al. Actinomycin D induces high-level resistance to thymidine analogs in replication ofhuman immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression. J Virol 2003; 77: 1011-20.
47. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of(R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob Agents Chemother 1993; 37: 332-8.
48. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14: 1824-9.
49. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42: 612-7.
50. Perigaud C, Aubertin AM, Benzaria S, Pelicano H, Girardet JL, Maury G, et al. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′, 3′ -dideoxythymidine. Biochem Pharmacol 1994; 48: 11-14.
51. Balzarini J, Karlsson A, Aquaro S, Perno CF, Cahard D, Naesens L, et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci USA 1996; 93: 7295.
52. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent _1592U89. Antimicrob Agents Chemother 1997; 41: 1099-107.
53. Vince R, Hua M, Brownell J, Daluge S, Lee F, Shannon WM, et al. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem Biophys Res Commun 1988; 156: 1046-53.
54. Garvey EP, Krenitsky TA. A novel human phosphotransferase highly specific for adenosine. Arch Biochem Biophys 1992; 296: 161-9.
55. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl[cytosine. Antimicrob Agents Chemother 1992; 36: 2423-31.
56. Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 1999; 13: 1511-7.
57. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14: 1824-9.
58. Huang H, Chopra R, Verdine GL, Harrison S. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-75.
59. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance; 1999-2000. Int Antiviral News 2000; 7: 46-69.
60. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′, 3′-dideoxycytidine and 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38: 275-81.
61. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, et al. Resistance to 2′, 3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994; 38: 282-7.
62. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse trariscriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41: 1094-8.
63. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4: 87-94.
64. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5653-6.
65. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875-81.
66. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′ -dideoxymosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′ -thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390-2.
67. Harrigan PR, Kinghorn I, Bloor S. Kemp SD, Najera I, Kolili A, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996; 70: 5930-4.
68. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, et al. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 1996; 70: 8010-8.
69. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-8.
70. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.
71. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34: 436-41.
72. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-64.
73. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′, 3′-didehydro-2′, 3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother 1994; 38: 1428-32.
74. Lin PF, Gonzalez CJ, Griffith B, Friedland Gs, Calvez V, Ferchal F, et al. Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther 1999; 4: 21-8.
75. Meyer PR, Matsuura SE, Mian AM, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
76. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophospliate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-17.
77. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998: 95: 13471-6.
78. Meyer PR, Matsuura SE, Schinazi RE, So AG, Scott WA. Differential removal of thymidine nucleofide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother 2000; 44: 3465-72.
79. Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother 2002; 46: 2179-84.
80. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 2001; 45: 2144-6.
81. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, et al. Lamivudine 3TC resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-32.
82. Ray AS, Murakami E. Peterson CN, Shi J, Schinazi RE, Anderson KS. Interactions of enantiomers of 2′, 3′-didehydro-2′, 3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Res 2002; 56: 189-205.
83. Feng JY, Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999; 38: 9440-8.
84. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue ofchain-terminated DNA synthesis. J Virol 2000; 74: 3579-85.
85. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000; 300: 403-18.
86. Chong Y, Akula N, Chu CK. Studies of molecular mechanism of tenofovir against 3TC- and AZT-resistance mutant HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2003; 13: 4019-22.
87. Ray AS, Basavapathruni A, Anderson KS. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002; 277: 40479-90.
88. Shirasaka T, Kavlick MF, Ueno T, Gan WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxyiiucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402.
89. Maeda Y, Venzon DJ, Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998; 17: 1207-13.
90. Kosalaraksa P, Kavlick ME, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999; 73: 5356-63.
91. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70: 1086-90.
92. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 2000; 74: 9339-46.
93. Deval J, Selmi B, Boretto J, Egloff MP, Guerreiro C, Sarfati S, et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem 2002; 277: 42097-104.
94. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75.
95. Imamichi T, Sinha T, Imamichi H, Zhang YM, Metcalf JA, Falloon J, et al. High-level resistance to 3′-azido-3′-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000; 74: 1023-8.
96. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, et al. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69. J Virol 2000; 74: 10958-64.
97. Imamichi T, Murphy MA, Imamichi H, Lane HC. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J Virol 2001; 75: 3988-92.
98. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriplase involves ATP-mediated excision. J Virol 2002; 76: 9143-51.
99. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA, Scott WA. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003; 77: 3871-7.
100. Mas A, Patera M, Briones C, Soriano V, Martinez MA, Domingo E, et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J 2000; 19: 575-61.
101. Mas A, Vazquez-Alvarez BM, Domingo E, Menendez-Arias L. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol 2002; 323: 181-97.
102. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995; 2: 293-302.
103. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991; 65: 4887-92.
104. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660-6.
105. Mellors JW, Dutschman GE, Im GJ, Tramontano E, Winkler SR, Cheng YC. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446-51.
106. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991; 88: 11241-5.
107. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000; 8: 1089-94.
108. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602-5.
109. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002; 269: 1670-7.
110. Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 2893-7.
111. Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem 2000; 43: 2019-30.
112. Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42: 1340-5.
113. Buckheit RW Jr, Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001; 45: 393-400.
114. Wlodawer A, Erickson JW. In: Richardson CC, Abelson JN, Meister A, Walsh CT. Eds, Ann Rev Biochem. Annual Review Inc., 1993; 62: 543-583.
115. Karacostas V, Nagashima K, Gonda MA, Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA 1989; 8: 8964-7.
116. Roberts NA, Martin JA, Kinchigton D, Broadhurst AV, Craig JC, Duncan IB, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 358-61.
117. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8: 153-64.
118. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-6.
119. Baldwin ET, Bhat TN, Liu B, Pattabiraman N, Erickson JW. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat Struct Biol 1995; 2: 244-9.
120. Baldwin ET, Bhat TN, Gulnik S, Liu B, Topol IA, Kiso Y, et al. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995; 3: 581-90.
121. Collins JR, Burt SK, Erickson JW. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat Struct Biol 1995; 2: 334-8.
122. Hong L, Zhang XC, Hartsuck JA, Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci 2000; 9: 1898-904.
123. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71: 6662-70.
124. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71: 1089-96.
125. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72: 7632-7.
126. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72: 3300-6.
127. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73: 3744-52.
128. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349-59.
129. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000; 49: 41-66.
130. Kaufmann D, Munoz M, Bleiber G, Fleury S, Lotti B, Martinez R, et al. Virological and immunological characteristics of HIV treatment failure. AIDS 2000; 14: 1767-74.
131. Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DE. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr 2000; 25; 289-95.
132. Robinson LH, Myers RE, Snowden BW, Tisdale M, Blair ED. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses 2000; 16: 1149-56.
133. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telentj A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001; 75: 3291-300.
134. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72: 7532-41.
135. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70: 3763-9.
136. Doyon L, Payant C, Brakier-Gingras L, Lamarre D. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 1998; 72: 6146-50.
137. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero J, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995 374: 569-71.
138. Craig C, Race E, Sheldon J, Whittaker L, Gilbert S, Moffatt A, et al. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998; 12: 1611-8.
139. Decks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35-43.
140. Dulioust A, Paulous S, Guillemot L, Delavalle AM, Bone F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999; 73: 850-4.
141. Fatkenheuer G, Hoetelmans RM, Hunn N, Schwenk A, Franzen C, Reiser M, et al. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. AIDS 1999; 13:1485-9.
142. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453-60.
143. Winters MA, Schapiro JM, Lawrence J, Merigan TC, Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998; 72: 5303-6.
144. Adkins JC, Faulds D. Amprenavir. Drugs 1998; 55: 837-42.
145. Drusano GL, D'Argenio DZ, Symonds W, Bilello PA, McDowell J, Sadler B, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998; 42: 2153-9.
146. Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999; 13: 661-7.
147. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999; 179: 808-16.
148. Parkin NT, Lie YS, Hellmann N, Markowitz M, Bonhoeffer S, Ho DD, et al. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis 1999; 180: 865-70.
149. Schmidt B, Kom K, Moschik B, Paatz C, Uberla K, Walter H. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother2000;44:3213-6.
150. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47: 1324-33.
151. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44: 2319-26.
152. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-24.
153. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, et al. Human serum attenuates tile activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250: 255-62.
154. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60.
155. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44: 2093-9.
156. Chong KT, Ruwart MJ, Hinshaw RR, Wilkinson KF, Rush BD, Yancey MF, et al. Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities. J Med Chem 1993; 36: 2575-7.
157. West ML, Fairlie DP. Targeting HIV-1 protease: a test of drug-design methodologies. Trend. Pharmaco Sci 1995; 16: 67-75.
158. Thaisrivongs S, Strohbach JW. Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999; 51: 51-8.
159. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001; 51: 151-77.
160. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. J Infect Dis 2001; 184: 519-23.
161. Murata H, Hruz PW, Mueckler M. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr Drug Targets Infect Disord 2002; 2: 1-8.
162. Hui DY, Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42: 81-92.
163. Borderi M, Farneti B, Tampellini L, Giuliani R, Verucchi G, Vescini F, et al. HIV-1, HAART and bone metabolism. New Microbiol 2002; 25: 375-84.
164. Corbett AH, Kashuba AD. Fosamprenavir. Vertex Pharmaceutical s/GlaxoSmithKline. Curr Opin Investig Drugs 2002; 3: 384-90.
165. Thaisrivongs S, Tomich PK, Watenpaugh KD, Chong KT, Howe WJ, Yang CP, et al. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994; 37: 3200-4.
166. Skulnick HI, Johnson PD, Howe WJ, Tomich PK, Chong KT, Watenpaugh KD, et al. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem 1995; 38: 4968-71.
167. Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, et al. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem 1996; 39: 3514-25.
168. Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol 1996; 3: 301-14.
169. Jadhav PK, Woerner FJ, Lam PY, Hodge CN, Eyermann CJ, Man HW, et al. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. J Med Chem 1998; 41: 1446-55.
170. Bold G, Fassler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem 1998; 41: 3387-401.
171. Turner SR, Strohbach JW, Tommasi RA, Aristoft PA, Johnson PD, Skulnick HL et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5, 6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41: 3467-76.
172. Yoshimura K, Kato R. Yusa K, Kavlick MF, Maroun V, Nguyen A, et al. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci USA 1999; 96: 8675-80.
173. Koh Y, Nakata H, Maeda K. Ogata H, Bilcer G, Devasamudram T, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-9.
174. Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol 2002; 76: 1349-58.
175. Kaltenbach RF 3rd, Trainor G, Getman D, Harris G, Garber S, Cordova B, et al. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother 2001; 45: 3021-8.
176. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41: 1058-63.
177. Larder BA, Hertogs K. Bloor S, van den Eynde CH, DeCian W, Wang Y, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14: 1943-8.
178. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
179. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro 4″-amino-2″, 2″ -dioxo-1″, 2″ - oxathiole-5″, 3′-[2′, 5′-bis-O-(tert-butyldimethylsilyl -beta-D-ribofuranosyl]]]-3-ethylthy mine. Biochemistry 2000; 39: 1427-33.
180. Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RW Jr, Covell DG, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997; 3: 341-5.
181. Berthoux L, Pechoux C, Darlix JL. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J Virol 1999; 73: 10000-9.
182. Mayasundari A, Rice WG, Diminnie JB, Baker DC. Synthesis, resolution, and determination of the absolute configuration of the enantiomers of cis-4, 5-dihydroxy-1, 2-dithiane 1, 1-dioxide, an HIV-INCp7 inhibitor. Bioorg Med Chem 2003; 11: 3215-9.
183. Loya S, Tal R, Kashman Y, Hizi A. Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1990; 34: 2009-12.
184. Min BS, Miyashiro H, Hattori M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother Res 2002; 16: S57-62.
185. Mohan P, Loya S, Avidan O, Verma S, Dhindsa GS, Wong MF, et al. Synthesis of naphthalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. J Med Chem 1994; 37: 2513-9.
186. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, et al. nhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 1997; 36: 3179-85.
187. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62: 398-405.
188. Gabbara S, Davis WR, Hupe L, Hupe D, Peliska JA. Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry 1999; 38: 13070-6.
189. Davis WR, Tomsho J, Nikam S, Cook EM, Somand D, Peliska JA. Inhibition of HIV-1 reverse transcriptase-catalyzed DNA strand transfer reactions by 4-chlorophenylhydrazone of mesoxalic acid. Biochemistry 2000; 39: 14279-91.
190. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R, et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-y1]-2, 4-dioxobutanoic acid. J Biol Chem 2003; 278: 2777-80.
191. Refaeli Y, Levy DN, Weiner DB. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci USA 1995; 92: 362-5.
192. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Kao GD, Muschel RJ, et al. HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci USA 1998; 95: 3419-24.
193. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-5.
194. Fletcher TM 3rd, Brichacek B, Sharova N, Newman MA, Stivahtis G, Sharp PM, et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 1996; 15: 6155-65.
195. Popov S, Rexach M, Zybarth G, Reding N, Lee MA, Ratner L. et al. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J 1998; 17: 909-17.
196. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-50.
197. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-7.
198. Davis WR, Gabbara S, Hupe D, Peliska JA. Actinomycin D inhibition of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry 1998; 37: 14213-21.
199. Guo J, Wu T, Bess J, Henderson LE, Levin JG. Actinomycin D inhibits human immunodeficiency virus type 1 minus-strand transfer in in vitro and endogenous reverse transcriptase assays. J Virol 1998; 72: 6716-24.
200. Jeeninga RE, Huthoff HT, Gultyaev AP, Berkhout B. The mechanism of actinomycin D-mediated inhibition of HIV-1 reverse transcription. Nucleic Acids Res 1998; 26: 5472-9.
201. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4.
202. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998; 15: 423-8.
203. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-94.
204. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoproteiin reversal in solid tumors. Eur J Cancer 1996; 32A: 1070-81.
205. Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemo sensitisers. Fur J Cancer 1996; 32: 991-1001.
206. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Design 2002; 8(8): 615-57.
207. el Kouni MH. Trends in the design of nucleoside analogues as anti-HIV drugs. Curr Pharm Design 2002; 8(8): 581-93.
208. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Design 2002; 8(8): 595-614.